Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in Illinois: - Rush - Copley Medical Center — Aurora, Illinois
- Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Loyola Center for Health at Burr Ridge — Burr Ridge, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Illinois: - Saint Anthony's Health — Alton, Illinois
- Rush - Copley Medical Center — Aurora, Illinois
- Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Loyola Center for Health at Burr Ridge — Burr Ridge, Illinois
Phase 3 Recruiting Network
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Sites in Illinois: - Saint Anthony's Health — Alton, Illinois
- Rush - Copley Medical Center — Aurora, Illinois
- Saint Joseph Medical Center — Bloomington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Loyola Center for Health at Burr Ridge — Burr Ridge, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …
Sponsor: Pfizer
NCT ID: NCT06152575
Sites in Illinois: - Endeavor Health - Swedish Hospital — Chicago, Illinois
- Endeavor Health - Evanston Hospital — Evanston, Illinois
- Endeavor Health - Glenbrook Hospital Ambulatory Care Center — Glenview, Illinois
- Endeavor Health - Highland Park Hospital Health Center 1 — Highland Park, Illinois
- Simmons Cancer Institute at SIU — Springfield, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Sites in Illinois: - University Of Illinois Medical Center — Chicago, Illinois
Phase 3 Recruiting Industry
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, inclu…
Sponsor: Kite, A Gilead Company
NCT ID: NCT06413498
Sites in Illinois: - University of Illinois Hospital and Health Sciences System — Chicago, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Sites in Illinois: - Loyola University Medical Center — Maywood, Illinois
Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT06158841
Sites in Illinois: - University of Illinois Hospital and Health Sciences System /ID# 246349 — Chicago, Illinois
- Rush University Medical Center /ID# 265690 — Chicago, Illinois
- Nancy W. Knowles Cancer Center /ID# 271361 — Elmhurst, Illinois
- Springfield Clinic - First /ID# 262266 — Springfield, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Sponsor: Bristol-Myers Squibb
NCT ID: NCT05827016
Sites in Illinois: - The University of Chicago Medical Center - Duchossois Center for Advanced Medicine — Chicago, Illinois
Phase 3 Recruiting Industry
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …
Sponsor: AstraZeneca
NCT ID: NCT07391657
Sites in Illinois: - Research Site — Chicago, Illinois
- Research Site — Park Ridge, Illinois
Phase 3 Recruiting Network
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as …
Sponsor: European Myeloma Network B.V.
NCT ID: NCT05243797
Sites in Illinois: - University of Illinois Medical Center at Chicago — Chicago, Illinois
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Illinois: - Cancer Treatment Centers of America-Chicago — Chicago, Illinois
Phase 2 Recruiting NIH
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06179888
Sites in Illinois: - University of Illinois — Chicago, Illinois
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in Illinois: - Northwestern Memorial Hospital — Chicago, Illinois
- University of Chicago Medical Center — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Sponsor: AstraZeneca
NCT ID: NCT05850234
Sites in Illinois: - Research Site — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in Illinois: - Northwestern — Chicago, Illinois
Phase 2 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called r…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07266441
Sites in Illinois: - Cancer Care Specialists of Central Illinois — O'Fallon, Illinois
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT04634552
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 2 Recruiting Network
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be a…
Sponsor: Multiple Myeloma Research Consortium
NCT ID: NCT06171685
Sites in Illinois: - University of Chicago Cancer Center — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 …
Sponsor: Sanofi
NCT ID: NCT04643002
Sites in Illinois: - University of Illinois-Chicago - College of Medicine- Site Number : 8400007 — Chicago, Illinois
Phase 2 Recruiting Academic/Other
This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)
Sponsor: University of Illinois at Chicago
NCT ID: NCT05344833
Sites in Illinois: - University of Illinois at Chicago — Chicago, Illinois
Phase 2 Recruiting Academic/Other
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not respond…
Sponsor: University of Chicago
NCT ID: NCT05789303
Sites in Illinois: - University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
Phase 1 Recruiting Industry
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
Sponsor: Poseida Therapeutics, Inc.
NCT ID: NCT04960579
Sites in Illinois: - City of Hope — Chicago, Illinois
- Advocate Aurora Health — Park Ridge, Illinois
Phase 1 Recruiting Industry
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, a…
Sponsor: AbbVie
NCT ID: NCT05650632
Sites in Illinois: - Hope And Healing Cancer Services /ID# 268536 — Hinsdale, Illinois
Phase 1 Recruiting Industry
The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of the study will evaluate different dose …
Sponsor: C4 Therapeutics, Inc.
NCT ID: NCT07280013
Sites in Illinois: - Loyola University Medical Center — Maywood, Illinois